Steqeyma is indicated for the treatment of plaque psoriasis and psoriatic arthritis in adult and pediatric patients, as well ...
HORSHAM, PA — Johnson & Johnson (NYSE: JNJ) has announced that the U.S. Food and Drug Administration (FDA) has approved ...
The FDA has approved guselkumab (Tremfya) as the first IL-23 inhibitor offering both subcutaneous and intravenous induction options for adults with moderate to severe active Crohn disease.
Celltrion has launched Steqeyma (ustekinumab-stba), its biosimilar of Stelara (ustekinumab), at list price at an 85% discount ...
South Korea’s Celltrion (Kosdaq: 068270) has announced the US launch of Steqeyma (ustekinumab-stba), a biosimilar to Stelara ...
US pharma major Johnson & Johnson (NYSE: JNJ) has won US approval for Tremfya (guselkumab) in the treatment of adults with ...
Pharmaceutical Technology on MSN1d
FDA approves Johnson & Johnson’s Tremfya to treat Crohn’s disease"FDA approves Johnson & Johnson’s Tremfya to treat Crohn’s disease" was originally created and published by Pharmaceutical ...
Celltrion announced the commercial launch of STEQEYMA® (ustekinumab-stba), a biosimilar of Janssen’s STELARA® (ustekinumab), in the United States. As we previously reported, the biosimilar was ...
It is available in both subcutaneous injection and intravenous infusion ... at an 85% discount to the current WAC list price of STELARA to help improve patient access to high-quality biologic ...
It encompasses all indications approved for the STELARA ® reference product ... STEQEYMA is available in both subcutaneous and intravenous formulations. The subcutaneous injection comes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback